Innovative Access Program

Through the Innovative Access Program we collaborate closely with academic experts, bringing our cutting edge antibody discovery technologies to the heart of novel target research. The extraordinary diversity of our immune repertoires streamlines target validation, transforming novel proteins into next generation therapeutic antibody programs.

Within 2 years, argenx’s Innovative Access Program with the Universite Catholique de Louvain / de Duve Institute has led to pioneering new work in the field of immuno-oncology, patented inventions on the novel immune checkpoint target GARP, and a comprehensive preclinical program with exciting development potential in oncology.

Contact us if you would like to discuss ways to bring argenx antibody discovery expertise to your academic research.